An in vitro approach to investigate ocular metabolism of a topical, selective β1-adrenergic blocking agent, betaxolol

References

• Al-Ghananeem AM, Crooks PA. (2007). Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery. Molecules 12:373–88
   PubMed Web of Science ®Google Scholar
• Barar J, Javadzadeh AR, Omidi Y. (2008). Ocular novel drug delivery: impacts of membranes and barriers. Expet Opin Drug Deliv 5:567–81
   PubMed Web of Science ®Google Scholar
• Campbell DA, Schoenwald RD, Duffel MW, Barfknecht CF. (1991). Characterization of arylamine acetyltransferase in the rabbit eye. Invest Ophth Vis Sci 32:2190–200
   PubMed Web of Science ®Google Scholar
• Dunne CE, Bushee JL, Argikar UA. (2013). Metabolism of bromopride in mouse, rat, rabbit, dog, monkey, and human hepatocytes. Drug Metab Pharmacokinet 28:453–61
   PubMed Web of Science ®Google Scholar
• Farag HH, Wu WM, Barros MD, et al. (1997). Ocular-specific chemical delivery systems of betaxolol for safe local treatment of glaucoma. Drug Des Discov 15:117–30
   PubMedGoogle Scholar
• Frishman WH, Kowalski M, Nagnur S, et al. (2001). Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade. Heart Dis 3:386–97
   PubMedGoogle Scholar
• Frishman WH, Tepper D, Lazar EJ, Behrman D. (1990). Betaxolol: a new long-acting beta 1-selective adrenergic blocker. J Clin Pharmacol 30:686–92
   PubMed Web of Science ®Google Scholar
• Fukano Y, Kawazu K. (2009). Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats. Drug Metab Dispos 37:1622–34
   PubMed Web of Science ®Google Scholar
• Gammons MV, Fedorov O, Ivison D, et al. (2013). Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Invest Ophthalmol Vis Sci 54:6052–62
   PubMed Web of Science ®Google Scholar
• Gevariya HB, Patel JK. (2013). Long acting betaxolol ocular inserts based on polymer composite. Curr Drug Deliv 10:384–93
   Google Scholar
• Girol AP, Mimura KK, Drewes CC, et al. (2013). Anti-inflammatory mechanisms of the annexin A1 protein and its mimetic peptide Ac2-26 in models of ocular inflammation in vivo and in vitro. J Immunol 190:5689–701
   Google Scholar
• Gunduz M, Argikar UA, Baeschlin D, et al. (2010). Identification of a novel N-carbamoyl glucuronide: in vitro, in vivo, and mechanistic studies. Drug Metab Dispos 38:361–7
   PubMed Web of Science ®Google Scholar
• Hermann P, Fraisse J, Allen J, et al. (1984). Determination of betaxolol, a new beta-blocker, by gas chromatography mass spectrometry: application to pharmacokinetic studies. Biomed Mass Spectrom 11:29–34
   Google Scholar
• Holló G, Whitson JT, Faulkner R, et al. (2006). Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration. Invest Ophth Vis Sci 47:235–40
   PubMed Web of Science ®Google Scholar
• Jain K, Kumar RS, Sood S, Dhyanandhan G. (2013). Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy. Curr Drug Deliv 10:493–9
   PubMed Web of Science ®Google Scholar
• Lee VH, Chien DS, Sasaki H. (1988). Ocular ketone reductase distribution and its role in the metabolism of ocularly applied levobunolol in the pigmented rabbit. J Pharmacol Exp Ther 246:871–8
   PubMed Web of Science ®Google Scholar
• Lee VH. (1983). Esterase activities in adult rabbit eyes. J Pharm Sci 72:239–44
   PubMed Web of Science ®Google Scholar
• Lesar TS. (1987). Comparison of ophthalmic beta-blocking agents. Clin Pharm 6:451–63
   PubMedGoogle Scholar
• Levin LA, Nilsson SFV, Hoeve JV, Qu SM. (2011). Adler’s Physiology of the eye. New York, NY: Saunders Elsevier Inc
   Google Scholar
• Ludden TM, Boyle DA, Gieseker D, et al. (1988). Absolute bioavailability and dose proportionality of betaxolol in normal healthy subjects. J Pharm Sci 77:779–83
   PubMed Web of Science ®Google Scholar
• Mohutsky MA, Wrighton SA, Ring BJ. (2008). In vitro metabolism: subcellular Fractions. In: Pearson PG, LC W, eds. Handbook of drug metabolism. New York: Informa Healthcare, 445–64
   Google Scholar
• Nakamura K, Fujiki T, Tamura HO. (2005). Age, gender and region-specific differences in drug metabolising enzymes in rat ocular tissues. Exp Eye Res 81:710–15
   PubMed Web of Science ®Google Scholar
• Phan TM, Nguyen KP, Giacomini JC, Lee DA. (1991). Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. J Ocul Pharmacol 7:243–52
   Google Scholar
• Quistad GB, Staiger LE, Schooley DA. (1986). The role of carnitine in the conjugation of acidic xenobiotics. Drug Metab Dispos 14:521–5
   Google Scholar
• Schmetterer L, Strenn K, Findl O, et al. (1997). Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers. Clin Pharmacol Ther 61:583–95
   PubMed Web of Science ®Google Scholar
• Schwartzman ML, Masferrer J, Dunn MW, et al. (1987). Cytochrome P450, drug metabolizing enzymes and arachidonic acid metabolism in bovine ocular tissues. Curr Eye Res 6:623–30
   PubMed Web of Science ®Google Scholar
• Sparks DL, Thomas TN, Buckholtz NS. (1981). Monamine oxidase activity in bovine retina: subcellular distribution and drug sensitivities. Neurosci Lett 21:201–16
   PubMed Web of Science ®Google Scholar
• Stagni G, Davis PJ, Ludden TM. (1991). Human pharmacokinetics of betaxolol enantiomers. J Pharm Sci 80:321–4
   PubMed Web of Science ®Google Scholar
• Ulrich RG, Bacon JA, Cramer CT, et al. (1998). Disruption of mitochondrial activities in rabbit and human hepatocytes by a quinoxalinone anxiolytic and its carboxylic acid metabolite. Toxicology 131:33–47
   PubMedGoogle Scholar
• Volotinen M, Maenpaa J, Kankuri E, et al. (2009). Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD. Invest Ophthalmol Vis Sci 50:3099–105
   PubMed Web of Science ®Google Scholar
• Watkins 3rd JB, Wirthwein DP, Sanders RA. (1991). Comparative study of phase II biotransformation in rabbit ocular tissues. Drug Metab Dispos 19:708–13
   PubMed Web of Science ®Google Scholar
• Wong YW, Ludden TM. (1990). Determination of betaxolol and its metabolites in blood and urine by high-performance liquid chromatography with fluorimetric detection. J Chromatogr 534:161–72
   PubMed Web of Science ®Google Scholar
• Zateyshchikov DA, Minushkina LO, Brovkin AN, et al. (2007). Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundam Clin Pharm 21:437–43
   PubMed Web of Science ®Google Scholar
• Zhang T, Xiang CD, Gale D, et al. (2008). Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition. Drug Metab Dispos 36:1300–7
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ. (1993). Topical ophthalmic beta blockers: a comparative review. J Ocul Pharmacol 9:373–84
   PubMedGoogle Scholar